Last reviewed · How we verify

Trazodone Hydrochloride prolonged-release tablets

Lee's Pharmaceutical Limited · Phase 1 active Small molecule

Trazodone Hydrochloride prolonged-release tablets is a Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently in Phase 1 development.

At a glance

Generic nameTrazodone Hydrochloride prolonged-release tablets
SponsorLee's Pharmaceutical Limited
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Trazodone Hydrochloride prolonged-release tablets

What is Trazodone Hydrochloride prolonged-release tablets?

Trazodone Hydrochloride prolonged-release tablets is a Small molecule drug developed by Lee's Pharmaceutical Limited.

Who makes Trazodone Hydrochloride prolonged-release tablets?

Trazodone Hydrochloride prolonged-release tablets is developed by Lee's Pharmaceutical Limited (see full Lee's Pharmaceutical Limited pipeline at /company/lee-s-pharmaceutical-limited).

What development phase is Trazodone Hydrochloride prolonged-release tablets in?

Trazodone Hydrochloride prolonged-release tablets is in Phase 1.

Related